Misplaced Pages

Flufenoxine

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
SNRI/SNDRI used to treat depression and other CNS pathologies (Alzheimer's)

Pharmaceutical compound
Flufenoxine
Clinical data
Other namesF-98214-TA
Identifiers
IUPAC name
  • 4-piperidine
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC18H20FNO
Molar mass285.362 g·mol
3D model (JSmol)
SMILES
  • C1CNCCC1C(C2=CC=CC=C2)OC3=CC(=CC=C3)F
InChI
  • InChI=1S/C18H20FNO/c19-16-7-4-8-17(13-16)21-18(14-5-2-1-3-6-14)15-9-11-20-12-10-15/h1-8,13,15,18,20H,9-12H2
  • Key:FDHPZDXAAGIHFC-UHFFFAOYSA-N

Flufenoxine (F-98214-TA) is a Serotonin–norepinephrine reuptake inhibitor. It can be used to treat disorders of the central nervous system, particularly depression and anxiety. It was developed by a Spanish company at the beginning of the 21st century.

Flufenoxine derivatives have been patented for the treatment of Alzheimer's disease.

Analogues of Flufenoxine were reported containing a duloxetine-type thiophene surrogate ring moiety. Such agents possess the desired triple-mode of activity (serotonin-noradrenaline and dopamine) (c.f. SNDRI).

For another related SNDRI agent see PC71812205. The racemic agent had IC50's of 11, 14, 190nM S~N>D.

References

  1. Artaiz I, Zazpe A, Innerárity A, Del Olmo E, Díaz A, Ruiz-Ortega JA, et al. (November 2005). "Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties". Psychopharmacology. 182 (3): 400–13. doi:10.1007/s00213-005-0087-3. PMID 16032410.
  2. Francisco Ledo Gómez, et al. WO2011147780 (Fabrica Espanola de Productos Quimicos y Farmaceuticos FAES SA).
  3. 郭强, et al. WO2015131814 (to WUHAN JIAYU TECHNOLOGY Co Ltd, Nhwa Pharmaceutical Corp).
  4. Ishichi, Yuji; Kimura, Eiji; Honda, Eiji; Yoshikawa, Masato; Nakahata, Takashi; Terao, Yasuko; Suzuki, Atsuko; Kawai, Takayuki; Arakawa, Yuuichi; Ohta, Hiroyuki; Kanzaki, Naoyuki; Nak-agawa, Hideyuki; Terauchi, Jun (2013). "Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-piperidine and related compounds". Bioorganic & Medicinal Chemistry. 21 (15): 4600–4613. doi:10.1016/j.bmc.2013.05.025.
  5. Ishichi Yuji, Kimura Eiji &Terauchi Jun, WO2010016554 (to Takeda).
Antidepressants (N06A)
Specific reuptake inhibitors and/or receptor modulators
SSRIsTooltip Selective serotonin reuptake inhibitors
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors
NRIsTooltip Norepinephrine reuptake inhibitors
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants
SARIsTooltip Serotonin antagonist and reuptake inhibitors
SMSTooltip Serotonin modulator and stimulators
Others
Tricyclic and tetracyclic antidepressants
TCAsTooltip Tricyclic antidepressants
TeCAsTooltip Tetracyclic antidepressants
Others
Monoamine oxidase inhibitors
Non-selective
MAOATooltip Monoamine oxidase A-selective
MAOBTooltip Monoamine oxidase B-selective
Adjunctive therapies
Miscellaneous
Monoamine reuptake inhibitors
DATTooltip Dopamine transporter
(DRIsTooltip Dopamine reuptake inhibitors)
NETTooltip Norepinephrine transporter
(NRIsTooltip Norepinephrine reuptake inhibitors)
SERTTooltip Serotonin transporter
(SRIsTooltip Serotonin reuptake inhibitors)
VMATsTooltip Vesicular monoamine transporters
Others
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins
Categories: